Female Sexual Distress Scale—Revised

Abstract

The Female Sexual Distress Scale—Revised (FSDS-R) is a standardized, self-administered patient-reported outcome (PRO) measure engineered to quantify the frequency and severity of sexually related personal distress experienced by women. Developed as an extension of the original 12-item Female Sexual Distress Scale (FSDS), the FSDS-R incorporates a specific 13th item focused explicitly on distress related to low sexual desire. This adaptation directly aligns the instrument with the diagnostic requirements of diagnostic nosologies such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR and DSM-5) and the International Classification of Diseases (ICD-10/ICD-11), both of which mandate that a diagnosis of female sexual dysfunction (FSD)—including Hypoactive Sexual Desire Disorder (HSDD) or Female Sexual Interest/Arousal Disorder (FSIAD)—requires marked personal distress or interpersonal difficulty.

The FSDS-R consists of 13 items scored on a 5-point Likert-type frequency metric ranging from 0 (Never) to 4 (Always), yielding a total score between 0 and 52 over a 30-day or 7-day recall window. Extensive psychometric evaluations demonstrate high internal consistency (Cronbach’s alpha > .88 to .95), strong test-retest reliability (intraclass correlation coefficients > .80), and well-established discriminant, convergent, and construct validity. A clinical cut-off score of ≥ 11 distinguishes women meeting diagnostic criteria for sexually related personal distress from functional populations. Widely recognized as a regulatory gold standard in clinical trials evaluated by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the FSDS-R provides a critical bridge between physiological manifestations of sexual response and the subjective emotional sequelae central to sexual health and quality of life.

Keywords

Female Sexual Distress Scale—Revised, FSDS-R, Hypoactive Sexual Desire Disorder, HSDD, female sexual dysfunction, sexual distress, psychometrics, patient-reported outcome, sexual health, construct validity

Authors

The development, revision, and psychometric validation of the Female Sexual Distress Scale and its revised variant (FSDS-R) were conducted by a consortium of clinical psychometricians, sexual medicine researchers, and industry specialists:

• Leonard R. Derogatis, Ph.D. — Center for Sexual Medicine at Sheppard Pratt Health System; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
• Robert Pyke, M.D., Ph.D. — Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States.
• Julie McCormack, M.S. — United BioSource Corporation, Bethesda, Maryland, United States.
• Adria Hunter, M.S. — United BioSource Corporation, Bethesda, Maryland, United States.
• Gale Harding, M.A. — United BioSource Corporation, Bethesda, Maryland, United States.
• Anita H. Clayton, M.D. — Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States (Co-investigator on pivotal validation trials).
• Raymond C. Rosen, Ph.D., Sandra R. Leiblum, Ph.D., Arthur L. Burnett, M.D., and Julia R. Heiman, Ph.D. — Members of the original American Foundation for Urologic Disease (AFUD) Expert Consensus Panel responsible for the parent FSDS instrument.

Correspondence regarding the instrument has historically been addressed to Leonard R. Derogatis, Ph.D., Johns Hopkins Department of Psychiatry and Behavioral Sciences, Center for Sexual Medicine at Sheppard Pratt, Baltimore, MD 21285.

Purpose

The primary purpose of the Female Sexual Distress Scale—Revised is to provide a reliable, valid, and sensitive psychometric instrument that explicitly measures sexually related personal distress in women. Historically, clinical research and sexual medicine encountered substantial difficulties operationalizing sexual dysfunction because physiological or behavioral manifestations of sexual dysfunction (such as reduced lubrication, decreased frequency of intercourse, or diminished orgasmic capacity) do not universally translate into psychological distress. Both the DSM nosology and consensus guidelines from the International Consultations on Sexual Medicine (ISSM) explicitly dictate that impaired sexual response parameters can only be diagnosed as a pathology if the woman experiences clinically significant distress or interpersonal conflict.

Prior to the development of the FSDS and FSDS-R, investigators frequently relied on generic health-related quality of life or psychological distress inventories, such as the Symptom Checklist-90-Revised (SCL-90-R), which lacked content validity for sexuality-specific emotional burdens. The FSDS-R addresses this gap by isolating the unique affective reactions elicited by impaired sexual functioning—specifically feelings of guilt, frustration, inadequacy, embarrassment, relational dissatisfaction, and despondency.

In clinical trials, the FSDS-R serves as a primary or secondary coprimary endpoint alongside measures of sexual function (such as the Female Sexual Function Index [FSFI] or Decreased Sexual Desire Screener [DSDS]). Its presence in pharmaceutical research has been fundamental to obtaining regulatory approvals for interventions aimed at treating generalized, acquired HSDD in premenopausal and postmenopausal women (e.g., flibanserin, bremelanotide). In everyday clinical practice, sex therapists, gynecologists, and psychiatrists use the tool for diagnostic screening, establishing baseline distress severity, tracking treatment response over time, and opening therapeutic dialogue around sensitive psychological constructs that patients may struggle to articulate spontaneously.

Psychological Construct

The core psychological construct measured by the FSDS-R is sexually related personal distress. Within contemporary psychometrics and clinical sexology, personal distress is understood as a multidimensional negative affective state triggered by cognitive appraisals of perceived sexual dysfunction or sexual dissatisfaction. The FSDS-R operationalizes this construct across several interconnected psychological dimensions:

1. Frustration and Tension

Items such as “Frustrated by your sexual problems” (Item 4) and “Stressed about sex” (Item 5) tap into the physiological and psychological activation associated with unmet sexual expectations, thwarted appetitive motivations, and anticipatory anxiety regarding sexual encounters. This dimension captures chronic apprehension and elevated arousal states that conflict with relaxed sexual engagement.

2. Self-Deprecation and Devaluation

Items such as “Inferior because of sexual problems” (Item 6) and “Sexually inadequate” (Item 8) capture the internalization of sexual difficulties into the broader self-concept. In societies with pervasive normative standards regarding female sexual responsiveness, difficulties with desire, arousal, or orgasm often lead to cognitive distortions where the self is judged as broken, incomplete, or failing. This cognitive self-blame generates depressive affect and feelings of inferiority relative to peers or societal archetypes.

3. Moral and Relational Self-Conscious Affect

Items such as “Guilty about sexual difficulties” (Item 3), “Embarrassed about sexual problems” (Item 10), and “Unhappy about your sexual relationship” (Item 2) probe complex secondary emotions. Sexual guilt typically emerges from perceived failure to satisfy a partner or maintain dyadic intimacy, leading women to interpret their sexual symptoms as moral failures or relationship transgressions. Embarrassment reflects shame and social exposure fears, which frequently block healthcare-seeking behaviors.

4. Affective Dissatisfaction and Dysphoria

Items such as “Distressed about your sex life” (Item 1), “Dissatisfied with your sex life” (Item 11), “Angry about your sex life” (Item 12), and “Regrets about your sexuality” (Item 9) measure overarching dissatisfaction, chronic grief, and resentment directed either at the dysfunction itself, the partner, or the loss of prior sexual health.

5. Desire-Specific Bother

Item 13 (“Bothered by low sexual desire”) uniquely focuses on distress stemming from deficient libido. Low desire is the most prevalent female sexual complaint, but it does not always cause distress; when it does, the individual consciously grieves the loss of erotic interest, longing, and responsiveness. Item 13 explicitly captures this specific cognitive-emotional burden, functioning both as a core constituent of the total score and as an independent diagnostic marker for HSDD.

Theoretical Framework

The FSDS-R is grounded in biopsychosocial models of sexual health and cognitive-behavioral theories of emotional distress. Key theoretical roots include the Transactional Model of Stress and Coping developed by Richard Lazarus and Susan Folkman, alongside Basson’s Non-Linear Model of Female Sexual Response.

Under Lazarus and Folkman’s transactional paradigm, distress does not arise directly from a biological impairment (e.g., lower vasoactive intestinal polypeptide or diminished central dopaminergic activity). Instead, distress is the product of primary appraisal (evaluating a sexual event or state as harmful, threatening, or indicative of personal failure) and secondary appraisal (perceiving that one lacks the interpersonal, medical, or psychological resources to cope with or resolve the deficit). When a woman appraises low desire or lubrication deficits as a direct threat to her romantic bond, femininity, or self-worth, high levels of subjective distress are evoked. The FSDS-R measures the frequency and severity of these appraised emotional impacts.

Furthermore, Rosemary Basson’s non-linear model conceptualizes female sexual response as circular and motivated primarily by emotional intimacy rather than spontaneous visceral hunger alone. In this framework, female sexual dysfunction emerges when negative psychological outcomes (such as anticipation of failure, guilt, or partner resentment) disrupt the feedback loop, discouraging emotional willingness to engage in sexual stimuli. The FSDS-R operationalizes precisely the negative psychological feedback loops that keep women trapped in sexual dysfunction cycles. By quantifying these maladaptive affective appraisals, the instrument provides an empirical index of the cognitive and emotional interference preventing healthy intimacy.

Validity

The psychometric validity of the FSDS-R has been extensively confirmed in diverse clinical, epidemiological, and pharmacological samples worldwide.

Content Validity and Saturation

Content validity was confirmed through qualitative saturation interviewing and cognitive debriefing in adult women with generalized acquired HSDD (Derogatis, Clayton, et al., 2008; Derogatis, Pyke, et al., 2008). In these investigations, informational saturation was reached within 25 subjects, with participants rating the items as exceptionally clear, relevant, and representative of their lived experiences. Item 13 (“Bothered by low sexual desire”) achieved the highest individual relevance rating (mean = 3.33 on a 0–4 scale), with 56% of respondents noting that Item 13 comprehensively captured their overall distress regarding deficient sexual drive.

Discriminant and Known-Groups Validity

Discriminant validity has been demonstrated by comparing clinical cohorts against sexually functional control groups. In the pivotal validation trial conducted across multiple North American academic centers (Derogatis, Clayton, et al., 2008), mean baseline FSDS-R total scores differed markedly across diagnostic groups:

• Women with Hypoactive Sexual Desire Disorder (HSDD; n = 136): Mean score ≈ 28.5 (SD ± 10.4)
• Women with other Female Sexual Dysfunctions (FSAD or FOD; n = 48): Mean score ≈ 24.8 (SD ± 11.2)
• Sexually functional control women (no FSD; n = 75): Mean score ≈ 6.7 (SD ± 7.1)

These differences were highly statistically significant (p < .001 at all observational points). Receiver Operating Characteristic (ROC) curve analyses yielded an area under the curve (AUC) exceeding 0.90, confirming superior diagnostic discrimination. An empirical cut-off score of ≥ 11 yielded optimal sensitivity (88%) and specificity (84%) for distinguishing clinical sexual distress from non-distressed normative populations.

Convergent and Criterion Validity

Convergent validity is documented through robust negative correlations between FSDS-R scores and domain scores of the Female Sexual Function Index (FSFI). Total FSDS-R scores correlate inversely with FSFI total scores (typically r = −.55 to −.70, p < .001) as well as FSFI desire, arousal, satisfaction, and orgasmic subscales. Conversely, the FSDS-R demonstrates significant positive correlations with general depression inventories (e.g., BDI-II) and anxiety measures, yet maintains sufficient divergent validity to confirm that it measures a distinct sexuality-specific construct rather than broad generalized demoralization.

Reliability

The FSDS-R possesses excellent reliability parameters across internal consistency, test-retest stability, and equivalence between recall windows.

Internal Consistency

Across validation trials involving pre- and postmenopausal women with HSDD, other FSDs, and healthy controls, Cronbach’s coefficient alpha values consistently range between .88 and .95:

• Baseline (Day 0) in HSDD cohort: α = .91 to .93
• Subsequent visits (Day 7, Day 28): α = .92 to .95
• Control cohort: α = .88 to .91

These values indicate high item interrelatedness without redundant item content.

Test-Retest Reliability

Temporal stability was evaluated in non-treatment validation designs over a 4-week period. The Intraclass Correlation Coefficient (ICC) for the total FSDS-R score between Day 0 and Day 28 was .88 in clinically stable women. For standalone Item 13, the ICC was .83, demonstrating strong temporal stability in the absence of therapeutic intervention.

Recall Period Equivalence

Studies evaluating the standard 30-day recall period against an accelerated 7-day recall protocol confirmed psychometric equivalence (concordance correlation > .90), providing investigators flexibility in clinical trial designs where rapid drug action or tight observation windows are monitored.

Factor Analysis

Initial exploratory factor analysis (EFA) on the original 12-item FSDS demonstrated a stable, predominantly unidimensional structure. When the 13th item was introduced to form the FSDS-R, comprehensive EFA and confirmatory factor analysis (CFA) procedures were conducted to determine whether the scale retained its parsimonious single-factor architecture or separated into multi-dimensional components.

Model Fit and Factor Solutions

Factor analytical investigations demonstrate that a single overarching latent construct—Sexually Related Personal Distress—accounts for the vast majority of shared variance (typically > 55% to 65% of the total variance). In CFA models testing a single-factor configuration:

• Comparative Fit Index (CFI): > .94 to .97
• Tucker-Lewis Index (TLI): > .93 to .96
• Root Mean Square Error of Approximation (RMSEA): .055 to .072 (90% CI [.045, .081])
• Standardized Root Mean Square Residual (SRMR): < .045

Factor Loadings

Standardized factor loadings across all 13 items in the single-factor model are uniformly high, confirming that each item contributes meaningfully to the common distress construct:

• Item 1 (Distressed about your sex life): λ = .81 to .87
• Item 2 (Unhappy about your sexual relationship): λ = .72 to .78
• Item 3 (Guilty about sexual difficulties): λ = .70 to .76
• Item 4 (Frustrated by your sexual problems): λ = .83 to .89
• Item 5 (Stressed about sex): λ = .82 to .88
• Item 6 (Inferior because of sexual problems): λ = .75 to .81
• Item 7 (Worried about sex): λ = .78 to .84
• Item 8 (Sexually inadequate): λ = .79 to .85
• Item 9 (Regrets about your sexuality): λ = .66 to .73
• Item 10 (Embarrassed about sexual problems): λ = .68 to .75
• Item 11 (Dissatisfied with your sex life): λ = .84 to .90
• Item 12 (Angry about your sex life): λ = .74 to .80
• Item 13 (Bothered by low sexual desire): λ = .76 to .83

Although some bi-factor models suggest minor second-order clusters (e.g., self-evaluative distress vs. partner/relational distress), the robust magnitude of the first unrotated eigenvalue and the strong uniform factor loadings justify calculating and interpreting a single, composite total score in research and clinical protocols.

Instrument / Measurement Tool

The characteristics, administration parameters, and scoring protocols for the Female Sexual Distress Scale—Revised are summarized below:

• Instrument Name: Female Sexual Distress Scale—Revised (FSDS-R)
• Instrument Type: Self-administered Patient-Reported Outcome (PRO) questionnaire / Psychometric rating scale
• Target Population: Adult premenopausal and postmenopausal women presenting with, or evaluated for, female sexual dysfunctions (notably HSDD, FSAD, and FOD)
• Item Count: 13 items
• Recall Windows: Standard version utilizes a 30-day recall period; clinical trials may employ a validated 7-day recall adaptation
• Response Format: 5-point Likert-type frequency scale:
  • 0 = Never
  • 1 = Rarely
  • 2 = Occasionally
  • 3 = Frequently
  • 4 = Always
• Scoring Procedure:
  • Sum the numerical values assigned to each of the 13 items.
  • Minimum total score = 0; Maximum total score = 52.
  • Higher scores reflect greater degrees of sexually related personal distress.
  • Missing data rule: If more than two items are missing, the composite total score should generally be considered invalid. For single missing items, mean imputation of completed items can be used in standardized trial protocols.
• Clinical Cut-Off Score:
  • A total score of ≥ 11 represents the established threshold denoting clinically significant personal sexual distress.
  • Scores < 11 indicate an absence of clinically meaningful distress, typical of sexually functional populations.
• Standalone Domain Scoring: Item 13 (“Bothered by low sexual desire”, scored 0–4) can be evaluated independently as a secondary endpoint to track distress specific to sexual desire deficits.

Permissions & Fee and Test Year

The original Female Sexual Distress Scale (FSDS) was published in 2002 under the auspices of the American Foundation for Urologic Disease (AFUD). The revised instrument (FSDS-R) was validated and introduced in 2008 by Leonard R. Derogatis, Ph.D., and colleagues. The instrument and its intellectual property are protected by international copyright laws (Copyright © 2000, 2002, 2008 by the American Foundation for Urological Disease, Inc., with licensing and commercial rights managed through author agreements and associated foundations).

Licensing and Accessibility: The FSDS-R is not in the public domain. While academic clinicians and independent non-commercial researchers may obtain permission to use the scale upon formal request to the copyright holders, commercial entities (such as pharmaceutical corporations and contract research organizations) are subject to licensing agreements and user fees. Translation certificates, electronic clinical outcome assessment (eCOA) licensing, and linguistic validations across dozens of international languages are administered through professional psychometric clearinghouses and clinical outcome assessment licensing bodies. Inquiries regarding permissions and administration rights may be directed to Leonard R. Derogatis, Ph.D., Center for Sexual Medicine at Sheppard Pratt, Baltimore, MD.

References

The following peer-reviewed publications provide the empirical and theoretical foundations for the FSDS and FSDS-R:

• Basson, R., Berman, J., Burnett, A., Derogatis, L., Ferguson, D., Fourcroy, J., Goldstein, I., Graziottin, A., Heiman, J., Laan, E., Leiblum, S., Padma-Nathan, H., Rosen, R., Segraves, K., Segraves, R. T., Shabsigh, R., Sipski, M., Wagner, G., & Whipple, B. (2000). Report of the International Consensus Development Conference on Female Sexual Dysfunction: Definitions and classifications. The Journal of Urology, 163(3), 888–893. https://doi.org/10.1016/S0022-5347(05)67828-7
• Clayton, A. H., Valladares Juarez, E. M., Schifano, C. A., & Pyke, R. E. (2012). Flibanserin: A potential new approach to the treatment of hypoactive sexual desire disorder in premenopausal women. Expert Opinion on Pharmacotherapy, 13(13), 1969–1979. https://doi.org/10.1517/14656566.2012.712114
• Derogatis, L. R., Clayton, A., Lewis-D’Agostino, D., Wunderlich, G., & Fu, Y. (2008). Validation of the Female Sexual Distress Scale—Revised for assessing distress in women with Hypoactive Sexual Desire Disorder. The Journal of Sexual Medicine, 5(2), 357–364. https://doi.org/10.1111/j.1743-6109.2007.00699.x
• Derogatis, L. R., Pyke, R., McCormack, J., Hunter, A., & Harding, G. (2008). Content validity of the Female Sexual Distress Scale—Revised (FSDS-R) in women with Hypoactive Sexual Desire Disorder (HSDD). The Journal of Sexual Medicine, 5(Suppl 5), 362–363.
• Derogatis, L. R., Rosen, R., Leiblum, S., Burnett, A., & Heiman, J. (2002). The Female Sexual Distress Scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal distress in women. Journal of Sex & Marital Therapy, 28(4), 317–330. https://doi.org/10.1080/009262302760328280
• Rosen, R., Brown, C., Heiman, J., Leiblum, S., Meston, C., Shabsigh, R., Ferguson, D., & D’Agostino, R. (2000). The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy, 26(2), 191–208. https://doi.org/10.1080/00926230050125901

13. Items of the Scale (Questionnaire)